raavrh74.mck.galgt2
Gene therapyexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2016 (NCT02704325)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Beta-1,4 N-acetylgalactosaminyltransferase 2Supplementation
supplementation - GALGT2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- raavrh74.mck.galgt2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03333590 | Phase 1/Phase 2 (Phase 2) | Nov 6, 2017 | Ohio State University |
| NCT02704325 | Phase 1 | Apr 1, 2016 | Ohio State University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ohio State University | Academic/Hospital | 2 | 2 | 2 | 2016 |
1 organizations
Page 1 / 1